ORMP

Oramed Pharmaceuticals Inc. (ORMP) | Rumor.io

Oramed Pharmaceuticals

ORMP

Attention (50-day avg)0%

Attention rank (50-day avg)#3,607

Bullish sentiment (50-day avg)100%

Price to earnings ratio1.14

Market capitalization194.4M

Earnings per share4.13

Dividend yield (TTM)5.29%

Revenue (annual)2M

Net income (annual)64M

Social

What share of all stock conversation is about ORMP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Jul 23

The price of ORMP is $4.02, with no change noted in the messages.
The posts express a bullish sentiment and encourage loading up on shares, with some mentioning the potential for a fast price increase.
There is a possibility of a breakout or a surprise in the market, with some traders advising to act quickly and not sleep on the opportunity.

Generated by AI

Sentiment

Of the messages about ORMP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	100% +45.45
Bearish	—	—	0%	0% -45.45

Bullish· May 19

$ORMP surged 15.57% today as Dr. Miriam Kidron, Oramed's Chief Scientific Officer, presents their oral delivery tech and Phase 3 trial insights at a diabetes summit in Boston.
Big volume few days back still looking for the $5 target, could be a popper tomorrow over $4.15.
ORMP has a better Quick Ratio than 96% of its industry peers.

Bearish· May 15

$ORMP's recent price drop may be a sign of selling slowing down, potentially reversing soon, with a falling wedge setup.
The company's past performance has been bearish, with a significant price drop to $2.00 following disappointing results from a diabetes study.
Shorting $ORMP has been a successful strategy, with some investors reporting profits after selling their shares at a loss, while others are waiting for the stock to drop below a certain price.

Generated by AI

Topics

Of the messages about ORMP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	72.43%
Analysts	—	—	0%	0%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	9.19%
Technical Analysis	—	—	0%	18.38%

Announcements· May 15

Oramed Pharmaceuticals' Chinese partner, Hefei Tianhui Biotechnology, has successfully completed its Phase 3 trials of oral insulin in Type 2 diabetes patients in China.
The company has submitted the data to the National Medical Products Administration for regulatory approval in China.
Oramed has also completed an analysis of its U.S.-based Phase 3 oral insulin trial data, showing significant lowering of A1C levels in patient subgroups.

Technical Analysis· Mar 22

ORMP has gapped up on news of developing a single-dose oral COVID vaccine, but is currently seeing low volume.
A breakout level for ORMP is expected after $11.50-$11.71.
A classic cup and handle formation base pattern is developing for ORMP, suggesting a potential new breakout higher.

Generated by AI

Community

Of the messages about ORMP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	14.29%	15.42%
Newcomers	100%	100%	85.71%	84.58%

Regulars· May 16

The price of Oramed Pharmaceuticals Inc. ($ORMP) has increased by 10.26% to $3.44, with a notable volume of 468k in the last 20 minutes.
The company's potential market size in China is significant, with 1.4 billion people at risk for diabetes, which could lead to substantial growth opportunities for Oramed Pharmaceuticals Inc.
The stock price of Oramed Pharmaceuticals Inc. has recovered from its previous low of almost $28, and some regulars are optimistic about its future potential, even predicting a price above $300.

Newcomers· Jul 23

Newcomers are focused on the potential for a quiet price to lead to a bullish setup and a possible increase in value.
Traders are optimistic about the company's future and are loading up on shares, citing the possibility of a low float and a surprise increase in volume.
Many are feeling bullish about the stock and are loading up on shares, with some anticipating a potential breakout and others warning to "don't sleep on this!"

Generated by AI

News

Type 2 Diabetes Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Ionis Pharma, Eli Lilly, Oramed Pharma, AstraZeneca, Novo Nordisk, Jiangsu

5d agoBarchart.com

Oramed Pharmaceuticals shareholders approve board, stock plan amendment at annual meeting

12d agoInvesting.com

Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP)

18d agoSeeking Alpha

Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee

WALTHAM, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension,” “Nano,” or the “Company”) today announced the appointment of Nadav Kidron to its Board of Directors (the “Board”). As part of the Board’s ongoing strategic review, led by Chairman Phillip Borenstein, the Board intends to establish a Strategy and Capital Allocation Committee to support the Board’s evaluation of capital allocation alternatives, potential returns of excess capital to shareholders

1mo agoYahoo Finance

Oramed: Q2 Earnings Snapshot

1mo agoYahoo Finance

Also Discussed

Investors talking about ORMP also mention

#	Name	Attention
1	Eocene Ltd.GLMD	0%0
2	Can-Fite BioPharma Ltd. ADRCANF	0%0
3	DECA - Denali Capital Acquisition Corp.	——
4	Scilex Holding Co.SCLX	0%new
5	Fidelity Disruptive Technology ETFFDTX	0%0
6	Rhinebeck Bancorp, Inc. Common StockRBKB	0%new
7	WEBs QQQ Defined Volatility ETFDVQQ	0%0
8	iShares Breakthrough Environmental Solutions ETFETEC	0%0
9	Rigetti Computing Inc. WarrantsRGTIW	0%-0.01
10	Baird Medical Investment Holdings Ltd.BDMD	0%new

Oramed Pharmaceuticals Inc.

Healthcare
Biotechnology

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on oral drug delivery solutions for medications that are traditionally administered by injection. The company develops proprietary technologies designed to make therapeutic proteins and peptides easier to administer in capsule form, with a particular emphasis on diabetes-related treatments and other biologic therapies. Its current product and development portfolio includes oral insulin programs, along with partnering and licensing activities that support broader applications for its delivery platform. Oramed Pharmaceuticals Inc. also participates in strategic collaborations and investment transactions tied to its biomedical assets, reflecting a business model that combines drug development with portfolio-based value creation. Headquartered in New York, the company operates within the pharmaceuticals and biotechnology market, where oral delivery platforms can play an important role in improving convenience and expanding the usability of complex medicines.

Website

Location

1185 Avenue of the Americas

New York, NY, 10036

United States

Social

What share of all stock conversation is about ORMP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Jul 23

The price of ORMP is $4.02, with no change noted in the messages.
The posts express a bullish sentiment and encourage loading up on shares, with some mentioning the potential for a fast price increase.
There is a possibility of a breakout or a surprise in the market, with some traders advising to act quickly and not sleep on the opportunity.

Generated by AI

Sentiment

Of the messages about ORMP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	100% +45.45
Bearish	—	—	0%	0% -45.45

Bullish· May 19

$ORMP surged 15.57% today as Dr. Miriam Kidron, Oramed's Chief Scientific Officer, presents their oral delivery tech and Phase 3 trial insights at a diabetes summit in Boston.
Big volume few days back still looking for the $5 target, could be a popper tomorrow over $4.15.
ORMP has a better Quick Ratio than 96% of its industry peers.

Bearish· May 15

$ORMP's recent price drop may be a sign of selling slowing down, potentially reversing soon, with a falling wedge setup.
The company's past performance has been bearish, with a significant price drop to $2.00 following disappointing results from a diabetes study.
Shorting $ORMP has been a successful strategy, with some investors reporting profits after selling their shares at a loss, while others are waiting for the stock to drop below a certain price.

Generated by AI

Topics

Of the messages about ORMP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	72.43%
Analysts	—	—	0%	0%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	9.19%
Technical Analysis	—	—	0%	18.38%

Announcements· May 15

Oramed Pharmaceuticals' Chinese partner, Hefei Tianhui Biotechnology, has successfully completed its Phase 3 trials of oral insulin in Type 2 diabetes patients in China.
The company has submitted the data to the National Medical Products Administration for regulatory approval in China.
Oramed has also completed an analysis of its U.S.-based Phase 3 oral insulin trial data, showing significant lowering of A1C levels in patient subgroups.

Technical Analysis· Mar 22

ORMP has gapped up on news of developing a single-dose oral COVID vaccine, but is currently seeing low volume.
A breakout level for ORMP is expected after $11.50-$11.71.
A classic cup and handle formation base pattern is developing for ORMP, suggesting a potential new breakout higher.

Generated by AI

Community

Of the messages about ORMP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	14.29%	15.42%
Newcomers	100%	100%	85.71%	84.58%

Regulars· May 16

The price of Oramed Pharmaceuticals Inc. ($ORMP) has increased by 10.26% to $3.44, with a notable volume of 468k in the last 20 minutes.
The company's potential market size in China is significant, with 1.4 billion people at risk for diabetes, which could lead to substantial growth opportunities for Oramed Pharmaceuticals Inc.
The stock price of Oramed Pharmaceuticals Inc. has recovered from its previous low of almost $28, and some regulars are optimistic about its future potential, even predicting a price above $300.

Newcomers· Jul 23

Newcomers are focused on the potential for a quiet price to lead to a bullish setup and a possible increase in value.
Traders are optimistic about the company's future and are loading up on shares, citing the possibility of a low float and a surprise increase in volume.
Many are feeling bullish about the stock and are loading up on shares, with some anticipating a potential breakout and others warning to "don't sleep on this!"

Generated by AI

Oramed Pharmaceuticals

Social

Jul 23

Bullish· May 19

Bearish· May 15

Announcements· May 15

Technical Analysis· Mar 22

Regulars· May 16

Newcomers· Jul 23

Type 2 Diabetes Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Ionis Pharma, Eli Lilly, Oramed Pharma, AstraZeneca, Novo Nordisk, Jiangsu

Oramed Pharmaceuticals shareholders approve board, stock plan amendment at annual meeting

Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP)

Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee

Oramed: Q2 Earnings Snapshot

Also Discussed

Oramed Pharmaceuticals Inc.

Company Information

Location

Type 2 Diabetes Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Ionis Pharma, Eli Lilly, Oramed Pharma, AstraZeneca, Novo Nordisk, Jiangsu

Oramed Pharmaceuticals shareholders approve board, stock plan amendment at annual meeting

Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP)

Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee

Oramed: Q2 Earnings Snapshot

Also Discussed

Social

Jul 23

Bullish· May 19

Bearish· May 15

Announcements· May 15

Technical Analysis· Mar 22

Regulars· May 16

Newcomers· Jul 23